CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Caribou Biosciences, Inc. - CRBU CFD

    5.30
    3.72%
    0.06
    最低: 5
    最高: 5.3
    Market Trading Hours* (UTC) Opens on Monday at 13:30

    Mon - Fri: 13:30 - 20:00

    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 0.06
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.024874%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.002651%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    关键数据
    前收盘价* 5.11
    开盘价* 5.08
    1 年变化* -44.96%
    日范围* 5 - 5.3
    52 周范围 4.12-13.19
    平均交易量（10 天） 515.24K
    平均交易量（3 个月) 9.90M
    市值 325.50M
    市盈率 -100.00K
    流通股 61.30M
    收入 13.85M
    EPS -1.63
    股息（收益率 %） N/A
    贝塔 -100.00K
    下一个财报发布日期 N/A

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平倉 Change Change (%) 開倉 High Low
    Mar 31, 2023 5.30 0.19 3.72% 5.11 5.30 4.98
    Mar 30, 2023 5.11 -0.04 -0.78% 5.15 5.25 4.90
    Mar 29, 2023 5.13 0.34 7.10% 4.79 5.18 4.67
    Mar 28, 2023 4.69 0.03 0.64% 4.66 4.87 4.54
    Mar 27, 2023 4.68 0.06 1.30% 4.62 4.78 4.49
    Mar 24, 2023 4.62 0.38 8.96% 4.24 4.69 4.18
    Mar 23, 2023 4.26 -0.11 -2.52% 4.37 4.43 4.10
    Mar 22, 2023 4.32 -0.43 -9.05% 4.75 4.75 4.31
    Mar 21, 2023 4.79 -0.08 -1.64% 4.87 4.90 4.74
    Mar 20, 2023 4.85 -0.04 -0.82% 4.89 4.91 4.69
    Mar 17, 2023 4.91 -0.02 -0.41% 4.93 5.02 4.80
    Mar 16, 2023 5.02 -0.07 -1.38% 5.09 5.15 4.91
    Mar 15, 2023 5.15 0.10 1.98% 5.05 5.25 5.02
    Mar 14, 2023 5.18 -0.25 -4.60% 5.43 5.51 5.10
    Mar 13, 2023 5.30 0.25 4.95% 5.05 5.34 5.02
    Mar 10, 2023 5.14 -0.29 -5.34% 5.43 5.48 4.93
    Mar 9, 2023 5.48 -0.35 -6.00% 5.83 5.85 5.33
    Mar 8, 2023 5.85 0.02 0.34% 5.83 5.92 5.75
    Mar 7, 2023 5.86 0.03 0.51% 5.83 6.04 5.70
    Mar 6, 2023 5.77 -0.32 -5.25% 6.09 6.09 5.54

    Caribou Biosciences, Inc. Events

    時間（協調世界時） (UTC) 國家 事件
    No events scheduled
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019
    总收入 13.851 9.598 12.361 5.788
    收入 13.851 9.598 12.361 5.788
    总营业费用 120.25 74.993 48.485 40.093
    销售/一般/行政费用，总计 38.02 24.322 14.06 16.458
    研究与开发 82.23 52.255 34.425 23.635
    营业收入 -106.399 -65.395 -36.124 -34.305
    利息收入（费用），非经营净值 -0.133 0.14 -0.517 3.337
    其他，净值 7.181 -1.347 0.514 0
    税前净收入 -99.351 -66.602 -36.127 -30.968
    税后净收入 -99.421 -66.923 -34.308 -23.431
    未计算非常项目前的净收益 -99.421 -66.923 -34.308 -23.431
    净收入 -99.421 -66.923 -34.308 -23.431
    普通股股东可获收益 (不含非经常性项目) -99.421 -66.923 -34.308 -23.431
    普通股股东可获收益 (含非經常性項目) -99.421 -66.923 -34.308 -23.431
    摊薄净收入 -99.421 -66.923 -34.308 -23.431
    摊薄后加权平均股 60.8011 60.2632 56.7092 56.7092
    扣除特别项目的每股摊薄盈利 -1.63518 -1.11051 -0.60498 -0.41318
    Dividends per Share - Common Stock Primary Issue 0 0 0
    每股正常摊薄盈利 -1.63518 -1.1276 -0.60498 -0.41318
    异常费用（收入） 0 -1.584
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    总收入 3.692 3.303 4.192 2.664 2.559
    收入 3.692 3.303 4.192 2.664 2.559
    总营业费用 34.27 29.84 32.623 23.517 22.964
    销售/一般/行政费用，总计 8.534 9.849 10.044 9.593 7.853
    研究与开发 25.736 19.991 22.579 13.924 15.111
    营业收入 -30.578 -26.537 -28.431 -20.853 -20.405
    利息收入（费用），非经营净值 -0.06 0.031 -0.016 0.163 0.076
    其他，净值 3.719 -0.141 1.75 1.602 2.171
    税前净收入 -26.919 -26.647 -26.697 -19.088 -18.158
    税后净收入 -26.989 -26.647 -26.697 -19.088 -18.479
    未计算非常项目前的净收益 -26.989 -26.647 -26.697 -19.088 -18.479
    净收入 -26.989 -26.647 -26.697 -19.088 -18.479
    普通股股东可获收益 (不含非经常性项目) -26.989 -26.647 -26.697 -19.088 -18.479
    普通股股东可获收益 (含非經常性項目) -26.989 -26.647 -26.697 -19.088 -18.479
    摊薄净收入 -26.989 -26.647 -26.697 -19.088 -18.479
    摊薄后加权平均股 61.01 60.8869 60.7577 60.5462 60.2632
    扣除特别项目的每股摊薄盈利 -0.44237 -0.43765 -0.4394 -0.31526 -0.30664
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -0.44237 -0.43765 -0.4394 -0.31526 -0.30664
    异常费用（收入） 0 0 0 0
    • 年度
    • 每季度
    2021 2020 2019
    流动资产总额 391.192 24.306 57.008
    现金和短期投资 375.832 15.953 49.471
    现金等价物 240.42 15.953 41.07
    短期投资 135.412 0 8.401
    应收账款总额，净额 8.124 5.16 3.982
    Accounts Receivable - Trade, Net 2.641 1.478 0.841
    Prepaid Expenses 6.565 2.433 3.182
    Other Current Assets, Total 0.671 0.76 0.373
    Total Assets 442.356 36.046 61.933
    Property/Plant/Equipment, Total - Net 4.887 3.502 4.332
    Property/Plant/Equipment, Total - Gross 8.964 6.598 6.59
    Accumulated Depreciation, Total -4.077 -3.096 -2.258
    Long Term Investments 45.302 7.626 0
    Other Long Term Assets, Total 0.975 0.612 0.593
    Total Current Liabilities 25.829 12.389 10.078
    Accounts Payable 3.99 2.601 2.537
    Accrued Expenses 12.089 8.151 5.653
    Notes Payable/Short Term Debt 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0.654 0
    Other Current Liabilities, Total 9.75 0.983 1.888
    Total Liabilities 54.531 18.16 13.147
    Total Long Term Debt 0 0.924 0
    Long Term Debt 0 0.924 0
    Deferred Income Tax 0.476 0.155 0.65
    Other Liabilities, Total 28.226 4.692 2.419
    Total Equity 387.825 17.886 48.786
    Preferred Stock - Non Redeemable, Net 0 41.323 41.323
    Common Stock 0.006 0.001 0.001
    Additional Paid-In Capital 485.748 7.433 4.025
    Retained Earnings (Accumulated Deficit) -97.794 -30.871 3.437
    Total Liabilities & Shareholders’ Equity 442.356 36.046 61.933
    Total Common Shares Outstanding 60.2632 56.7092 56.7092
    Other Equity, Total -0.135
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    流动资产总额 368.01 391.192 449.047 142.967 155.925
    现金和短期投资 353.731 375.832 435.31 129.524 145.924
    现金等价物 147.63 240.42 435.31 129.524 145.924
    应收账款总额，净额 6.037 8.124 7.785 8.407 5.825
    Accounts Receivable - Trade, Net 1.868 2.641 2.431 0.832 1.049
    Prepaid Expenses 7.276 6.565 5.189 3.759 3.096
    Other Current Assets, Total 0.966 0.671 0.763 1.277 1.08
    Total Assets 445.997 442.356 461.96 158.397 167.965
    Property/Plant/Equipment, Total - Net 31.765 4.887 4.477 4.408 3.38
    Property/Plant/Equipment, Total - Gross 36.15 8.964 8.282 7.952 6.695
    Accumulated Depreciation, Total -4.385 -4.077 -3.805 -3.544 -3.315
    Long Term Investments 44.758 45.302 7.626 7.626 7.626
    Other Long Term Assets, Total 1.464 0.975 0.81 3.396 1.034
    Total Current Liabilities 26.667 25.829 26.158 26.007 22.21
    Accounts Payable 1.814 3.99 3.482 4.029 3.117
    Accrued Expenses 11.215 12.089 12.288 11.034 10.929
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 0 0 0.655
    Other Current Liabilities, Total 13.638 9.75 10.388 10.944 7.509
    Total Liabilities 74.2 54.531 57.559 55.938 53.504
    Total Long Term Debt 0 0 0 0 0.926
    Long Term Debt 0 0 0 0.926
    Deferred Income Tax 0.476 0.476 0.155 0.155 0.155
    Other Liabilities, Total 47.057 28.226 31.246 29.776 30.213
    Total Equity 371.797 387.825 404.401 102.459 114.461
    Preferred Stock - Non Redeemable, Net 0 0 0 150.15 150.15
    Common Stock 0.006 0.006 0.006 0.001 0.001
    Additional Paid-In Capital 489.762 485.748 483.71 10.649 8.34
    Retained Earnings (Accumulated Deficit) -116.882 -97.794 -79.315 -58.341 -44.03
    Total Liabilities & Shareholders’ Equity 445.997 442.356 461.96 158.397 167.965
    Total Common Shares Outstanding 60.6896 60.2632 60.0213 59.9708 56.7092
    短期投资 206.101 135.412
    Other Equity, Total -1.089 -0.135
    • 年度
    • 每季度
    2022 2021 2020 2019
    净收入/起跑线 -99.421 -66.923 -34.308 -23.431
    经营活动产生的现金 -90.966 -32.519 -33.215 -32.006
    经营活动产生的现金 1.622 0.984 0.9 0.751
    非现金物品 11.037 4.353 0.016 -1.059
    Cash Taxes Paid 0 0.011 0.021 1.809
    营运资金的变化 -4.204 29.067 0.177 -8.267
    投资活动产生的现金 -93.249 -176.397 6.363 27.233
    资本支出 -6.454 -2.121 -0.317 -0.884
    其他投资现金流量项目，总计 -86.795 -174.276 6.68 28.117
    融资活动产生的现金 2.133 433.429 1.735 0.172
    股票的发行（报废），净额 2.133 432.398 1.848 0.217
    债务的发行（退还），净额 0 1.031 -0.113 -0.045
    现金净变化 -182.082 224.513 -25.117 -4.601
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Net income/Starting Line -99.421 -72.432 -45.785 -19.088 -66.923
    Cash From Operating Activities -90.966 -65.922 -43.546 -21.673 -32.519
    Cash From Operating Activities 1.622 1.116 0.666 0.308 0.984
    Non-Cash Items 11.037 9.47 4.942 2.215 4.353
    Cash Taxes Paid 0 0 0 0 0.011
    Cash Interest Paid 0
    Changes in Working Capital -4.204 -4.076 -3.369 -5.108 29.067
    Cash From Investing Activities -93.249 -94.419 -86.08 -72.107 -176.397
    Capital Expenditures -6.454 -4.697 -3.343 -0.723 -2.121
    Other Investing Cash Flow Items, Total -86.795 -89.722 -82.737 -71.384 -174.276
    Cash From Financing Activities 2.133 2.006 1.352 0.99 433.429
    Issuance (Retirement) of Stock, Net 2.133 2.006 1.352 0.99 432.398
    Issuance (Retirement) of Debt, Net 0 0 0 0 1.031
    Net Change in Cash -182.082 -158.335 -128.274 -92.79 224.513
    Financing Cash Flow Items 0
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    PFM Health Sciences, LP Hedge Fund 7.2754 4459783 -1540217 2022-12-31 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.6832 4096777 277588 2022-12-31 LOW
    Haurwitz (Rachel E. Ph.D.) Individual Investor 5.5129 3379395 10000 2023-03-20 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.2184 3198893 803423 2022-12-31 LOW
    Avidity Partners Management LP Hedge Fund 4.7025 2882600 -290000 2022-12-31 HIGH
    Rokos Capital Management LLP Hedge Fund 4.4831 2748139 840630 2022-12-31 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.1939 2570827 26789 2022-12-31 LOW
    Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 4.1662 2553878 -737020 2022-12-31 LOW
    Elmwood Wealth Management, INC. Investment Advisor 3.8569 2364240 0 2022-12-31 LOW
    EIDP Inc Corporation 3.3573 2058000 -1093311 2022-05-31 MED
    BofA Global Research (US) Research Firm 3.008 1843902 1668395 2022-12-31 LOW
    Fidelity Management & Research Company LLC Investment Advisor 2.3541 1443046 -547 2022-12-31 LOW
    Morgan Stanley & Co. LLC Research Firm 1.982 1214933 30615 2022-12-31 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.6819 1030987 45617 2022-12-31 LOW
    Alkeon Capital Management LLC Investment Advisor/Hedge Fund 1.4575 893424 -138016 2022-12-31 LOW
    Fidelity International Investment Advisor 1.404 860666 0 2022-12-31 LOW
    Assenagon Asset Management S.A. Investment Advisor 1.3944 854738 55247 2022-12-31 HIGH
    Maverick Capital, Ltd. Hedge Fund 1.0645 652542 0 2022-12-31 MED
    Tekla Capital Management LLC Investment Advisor 0.9252 567147 0 2022-12-31 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 0.9215 564855 -1059 2022-12-31 LOW

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    500K+

    交易者

    92K+

    每月活跃客户

    $53M+

    每月投资额

    $30M+

    每月提取金额

    交易計算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    貿易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投資
    交易規模（槓桿 x 投資）：
    開倉

    平倉

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/失利

    Caribou Biosciences, Inc. Company profile

    关于 Caribou Biosciences Inc.

    Caribou Biosciences, Inc.是一家位于美国的临床阶段的生物技术公司。 公司利用簇状规则间隔短回文重复（CRISPR）基因组编辑来发现和开发基于免疫细胞的癌症治疗方法。 该公司专注于开发针对一系列肿瘤类型的基因组编辑现成的CAR-T细胞和自然杀伤细胞（NK）疗法的管道。 它还在多个领域提供CRISPR-Cas9基础知识产权的许可，包括研究工具、内部研究使用、诊断和工业生物技术。 公司的管线包括CB-010、CB-011、CB-012和CB-020。

    Industry: Biotechnology & Medical Research (NEC)

    2929 7Th Street, Ste 120
    BERKELEY
    CALIFORNIA 94710
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    BTC/USD

    28,478.40 Price
    -0.040% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    Gold

    1,969.66 Price
    -0.550% 1D Chg, %
    多头隔夜费 -0.0185%
    空头隔夜费 0.0102%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    US100

    13,186.80 Price
    +1.680% 1D Chg, %
    多头隔夜费 -0.0249%
    空头隔夜费 0.0027%
    隔夜费时间 21:00 (UTC)
    价差 3.0

    Oil - Crude

    75.76 Price
    +1.830% 1D Chg, %
    多头隔夜费 -0.0156%
    空头隔夜费 -0.0063%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    还在找一位您可以信任的经纪商吗？

    加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易